EnginZyme
PrivateLast Round
Series C
Sep 23, 2026
Total Funding Raised
$47.21M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
EnginZyme operates in Healthcare & Life Sciences and is based in Solna. Its latest recorded funding round was a Series C round in September 2026.
EnginZyme is a biotechnology company that develops cell-free synthetic technology to enable sustainable biomanufacturing for the chemical industry.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clean Manufacturing
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EnginZyme Comparables
Compare EnginZyme with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| FabricNano | 81% | |
| Debut | 79% | |
| Enzymicals AG | 79% |
For institutional investors. Book with your work email.
EnginZyme Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 23, 2026 | ||||
| Series B | Dec 19, 2022 | ||||
| Series A Extension | Feb 11, 2021 | ||||
| Series A | Apr 21, 2020 | ||||
| Grant | Jan 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
EnginZyme Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bunge Ventures | Series B |
| SEB Group | Series A Extension, Series B |
| Navigare Ventures | Series C, Series B |
| Almi Invest AB | Series C, Series B |
| Industrifonden | Series C, Series B, Series A Extension |
| European Union's Horizon 2020 research and innovation programme (Marie Skłodowska-Curie) | Grant |
| Sofinnova Partners | Series C, Series A Extension, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 23, 2026
$9M round led by Valquest Partners
- Aug 21, 2026
Monthly visitors grew 181% MoM, reaching 6.9K.
For institutional investors. Book with your work email.
EnginZyme Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EnginZyme's valuation, stock price, and market status.
Is EnginZyme a public or private company?
EnginZyme is a private company.
What is the current stock price of EnginZyme?
EnginZyme is a private company, so its shares have no public market price. Caplight tracks EnginZyme's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EnginZyme worth (valuation)?
Valuation information for EnginZyme is not publicly available.
Can I buy EnginZyme stock?
EnginZyme shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EnginZyme's last funding round?
EnginZyme's most recent funding round was Series C on September 23, 2026.
Who are the main investors in EnginZyme?
Key investors in EnginZyme include Industrifonden, Sofinnova Partners, Valquest Partners.
Will EnginZyme IPO soon?
No public IPO plans have been announced for EnginZyme.
How can I track EnginZyme secondary market activity?
Caplight tracks bids, offers, and trades in EnginZyme's shares on secondary markets.